167 related articles for article (PubMed ID: 28476232)
21. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children.
Redlich A; Pamporaki C; Lessel L; Frühwald MC; Vorwerk P; Kuhlen M
Pediatr Blood Cancer; 2021 Jul; 68(7):e28981. PubMed ID: 33682326
[TBL] [Abstract][Full Text] [Related]
22. Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma.
Taïeb D; Pacak K
Cell Tissue Res; 2018 May; 372(2):393-401. PubMed ID: 29450723
[TBL] [Abstract][Full Text] [Related]
23. Genetics of pheochromocytoma and paraganglioma.
Wachtel H; Fishbein L
Curr Opin Endocrinol Diabetes Obes; 2021 Jun; 28(3):283-290. PubMed ID: 33764930
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
25. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
[TBL] [Abstract][Full Text] [Related]
26. The genetic landscape of pheochromocytomas and paragangliomas: somatic mutations take center stage.
Dahia PL
J Clin Endocrinol Metab; 2013 Jul; 98(7):2679-81. PubMed ID: 23837189
[No Abstract] [Full Text] [Related]
27. Novel hereditary forms of pheochromocytomas and paragangliomas.
Dahia PL
Front Horm Res; 2013; 41():79-91. PubMed ID: 23652672
[TBL] [Abstract][Full Text] [Related]
28. Genomic Landscape of Pheochromocytoma and Paraganglioma.
Jochmanova I; Pacak K
Trends Cancer; 2018 Jan; 4(1):6-9. PubMed ID: 29413423
[TBL] [Abstract][Full Text] [Related]
29. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
[TBL] [Abstract][Full Text] [Related]
30. Pheochromocytoma and paraganglioma: molecular testing and personalized medicine.
Burnichon N; Buffet A; Gimenez-Roqueplo AP
Curr Opin Oncol; 2016 Jan; 28(1):5-10. PubMed ID: 26599293
[TBL] [Abstract][Full Text] [Related]
31. Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas.
Evenepoel L; van Nederveen FH; Oudijk L; Papathomas TG; Restuccia DF; Belt EJT; de Herder WW; Feelders RA; Franssen GJH; Hamoir M; Maiter D; Ghayee HK; Shay JW; Perren A; Timmers HJLM; van Eeden S; Vroonen L; Aydin S; Robledo M; Vikkula M; de Krijger RR; Dinjens WNM; Persu A; Korpershoek E
J Clin Endocrinol Metab; 2018 Jan; 103(1):46-55. PubMed ID: 28938490
[TBL] [Abstract][Full Text] [Related]
32. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
[TBL] [Abstract][Full Text] [Related]
33. Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies.
Nölting S; Grossman AB
Endocr Pathol; 2012 Mar; 23(1):21-33. PubMed ID: 22391976
[TBL] [Abstract][Full Text] [Related]
34. Absence of BRAF mutation in pheochromocytoma and paraganglioma.
Vosecka T; Vicha A; Zelinka T; Jencova P; Pacak K; Duskova J; Benes J; Guha A; Stanek L; Kohoutova M; Musil Z
Neoplasma; 2017; 64(2):278-282. PubMed ID: 28043156
[TBL] [Abstract][Full Text] [Related]
35. [Pheochromocytomas and paragangliomas: implications of new insights for diagnosis and treatment].
van der Kleij-Corssmit EP; Havekes B; Vriends AH; Jansen JC; Romijn JA
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):489-93. PubMed ID: 18389879
[TBL] [Abstract][Full Text] [Related]
36. New insights into the genetics of familial chromaffin cell tumors.
Koch CA; Vortmeyer AO; Zhuang Z; Brouwers FM; Pacak K
Ann N Y Acad Sci; 2002 Sep; 970():11-28. PubMed ID: 12381538
[TBL] [Abstract][Full Text] [Related]
37. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma.
Burnichon N; Vescovo L; Amar L; Libé R; de Reynies A; Venisse A; Jouanno E; Laurendeau I; Parfait B; Bertherat J; Plouin PF; Jeunemaitre X; Favier J; Gimenez-Roqueplo AP
Hum Mol Genet; 2011 Oct; 20(20):3974-85. PubMed ID: 21784903
[TBL] [Abstract][Full Text] [Related]
38. [Hereditary paragangliomas and pheochromocytomas].
Gimenez-Roqueplo AP
Nephrol Ther; 2006 Jan; 2 Suppl 2():S137-42. PubMed ID: 17373214
[TBL] [Abstract][Full Text] [Related]
39. Succinate-Dehydrogenase Deficient Paragangliomas/Pheochromocytomas: Genetics, Clinical Aspects and Mini- Review.
Rusyn L; Kohn B
Pediatr Endocrinol Rev; 2017 Mar; 14(3):312-325. PubMed ID: 28508602
[No Abstract] [Full Text] [Related]
40. Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas.
Mannelli M; Castellano M; Schiavi F; Filetti S; Giacchè M; Mori L; Pignataro V; Bernini G; Giachè V; Bacca A; Biondi B; Corona G; Di Trapani G; Grossrubatscher E; Reimondo G; Arnaldi G; Giacchetti G; Veglio F; Loli P; Colao A; Ambrosio MR; Terzolo M; Letizia C; Ercolino T; Opocher G;
J Clin Endocrinol Metab; 2009 May; 94(5):1541-7. PubMed ID: 19223516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
